Delanzomib

DB11956InvestigationalSmall molecule

Delanzomib has been used in trials studying the treatment of Solid Tumors, Multiple Myeloma, and Lymphoma, Non-Hodgkin.

Mechanism: Pharmacologically active on Proteasome subunit beta type-1 and Proteasome subunit beta type-5
Curator reviewed
Formula / weight: C₂₁H₂₈BN₃O₅ · 413.28 g/mol (avg)
Code names: CEP-18770 · CIP-18770 · CT-47098 · NPH-007098

Resolves to

Compound

Structure

InChIKeySJFBTAPEPRWNKH-CCKFTAQKSA-NSMILESCC(C)C[C@H](NC(=O)[C@@H](NC(=O)C1=CC=CC(=N1)C1=CC=CC=C1)[C@@H](C)O)B(O)O

Targets

What you can answer from here — as of July 07, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Delanzomib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.